Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" by Huguet et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Is neoadjuvant folfox an effective treatment only in a very selected favorable subgroup of locally advanced rectal cancer?

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

[Informed consent in radiotherapy care].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Indication of radiotherapy for de novo metastatic cancer. The « Recommendations » Commission first issue.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Radiation therapy of the primary tumour and oligometastatic sites in patients with breast cancer with synchronous metastases: A literature review.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023

Related Experiment Video

Updated: May 8, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

[Intrinsic radiosensitivity: predictive assays that will change daily practice].

J Lacombe1, O Riou, J Solassol

  • 1Institut de recherche en cancérologie de Montpellier (IRCM), Inserm U896, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Avenue des Apothicaires, 34298 Montpellier cedex 05, France; Université Montpellier 1, avenue des Apothicaires, 34298 Montpellier cedex 05, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|September 4, 2013
PubMed
Summary
This summary is machine-generated.

Radiotherapy effectiveness relies on precise dosing, but healthy tissue damage causes side effects. Understanding individual radiosensitivity is key to improving radiation therapy outcomes.

Keywords:
Effets indésirablesLate effectsPredictive assaysRadiotherapyRadiothérapieTests radiosensibilité

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: May 8, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

  • Radiobiology
  • Radiation Oncology
  • Medical Physics

Context:

  • Radiotherapy aims for homogenous dose delivery to target volumes.
  • Dose to surrounding healthy tissues impacts treatment efficacy and toxicity.
  • Individual radiosensitivity contributes to variable late side effects in patients.

Purpose:

  • To review radiobiological approaches for understanding radiation-induced late effects.
  • To explore the clinical utility of predictive assays for radiosensitivity.

Summary:

  • This review examines radiobiological methods to elucidate mechanisms of radiation-induced late effects.
  • It highlights the existence of individual radiosensitivity influencing non-reversible side effects.
  • The potential clinical application of predictive assays is also discussed.

Impact:

  • Improved understanding of radiation-induced late effects.
  • Potential for personalized radiotherapy through predictive assays.
  • Enhanced therapeutic ratio in radiation treatments.